Vaxxas opens new facility in Brisbane, Australia for HD-MAP vaccines
Spread over 60,000ft2, the custom-built Vaxxas Biomedical Facility will act as the firm’s global headquarters to scale up…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
19 Jun 23
Spread over 60,000ft2, the custom-built Vaxxas Biomedical Facility will act as the firm’s global headquarters to scale up…
19 Jun 23
The study will use the proprietary combination of SciSparc's Palmitoylethanolamide and Clearmind's Methoxy-2-aminoindane, a proprietary psychedelic treatment for…
19 Jun 23
With the acquisition, Coherus will get access to Surface Oncology’s two differentiated clinical-stage assets, SRF388, a novel IL-27-targeted…
19 Jun 23
TGI-6 targets unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, enabling potent anti-tumor responses
19 Jun 23
BAT2206 is a proposed biosimilar to Janssen’s Stelara1, which is currently approved in Brazil for the treatment of…
16 Jun 23
Fruquintinib is a highly selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and…
16 Jun 23
In the study, Risankizumab achieved the primary endpoint of clinical remission at week 52 and met its key…
15 Jun 23
Under the partnership, Vial will support Nielsen for the Phase 3, randomised, double-blind, placebo-controlled clinical study of Candin…
15 Jun 23
Siemens Healthineers ActSafe solution leverages Medigate by Claroty software; medical device security data sharing boosts customers' risk management…
14 Jun 23
The NMPA approval was based on the results of Phase 3 REGAIN trial in which Soliris showed clinical…